Inovio Pharmaceuticals, Inc.
INO
$1.64
-$0.04-2.38%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -84.95M | -108.09M | -87.76M | -96.48M | -107.25M |
| Total Depreciation and Amortization | 2.99M | 3.01M | 3.03M | 3.11M | 3.13M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 2.55M | 22.30M | -1.79M | -2.24M | 2.71M |
| Change in Net Operating Assets | -9.22M | -6.14M | -8.27M | -6.59M | -2.67M |
| Cash from Operations | -88.63M | -88.92M | -94.79M | -102.19M | -104.08M |
| Capital Expenditure | -285.70K | -158.30K | -90.30K | -511.70K | -487.90K |
| Sale of Property, Plant, and Equipment | -- | 59.30K | 59.30K | 59.30K | 59.30K |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 14.33M | 48.84M | 53.98M | 59.09M | 104.50M |
| Cash from Investing | 14.04M | 48.74M | 53.95M | 58.64M | 104.07M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | 0.00 | 0.00 | 0.00 | -16.42M |
| Issuance of Common Stock | 36.17M | 22.12M | 14.85M | 31.98M | 36.10M |
| Repurchase of Common Stock | -110.80K | -110.80K | -115.40K | -320.70K | -420.70K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 16.99M | 33.05M | 16.06M | 32.21M | 32.21M |
| Cash from Financing | 53.05M | 55.06M | 30.80M | 63.87M | 51.48M |
| Foreign Exchange rate Adjustments | -- | 0.00 | 0.00 | 0.00 | 32.40K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -21.54M | 14.88M | -10.04M | 20.31M | 51.50M |